AA
JSPR icon

AlphaCentric Advisors’s Jasper Therapeutics JSPR Stock Holding History

AlphaCentric Advisors’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17,500
Closed -$329K – 252
2024
Q3 		$329K Buy
+17,500
New +$348K 0.24% 105

Other funds holding JSPR

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

AlphaCentric Advisors's JSPR Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Jasper Therapeutics (JSPR) in Q4 2024, closing a stake of 17,500 shares — an estimated $329K sold.

AlphaCentric Advisors first reported a position in JSPR in Q3 2024 and held it in 1 quarter. The position peaked at $329K in Q3 2024. 87 funds tracked by Wall St. Rank hold JSPR as of Q4 2024.

  • AlphaCentric Advisors reported no remaining Jasper Therapeutics position as of Q4 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 17,500 Jasper Therapeutics shares in Q4 2024, an estimated $329K.
  • AlphaCentric Advisors first reported a position in Jasper Therapeutics in Q3 2024 and held it in 1 quarter.
  • AlphaCentric Advisors's Jasper Therapeutics position peaked at $329K in Q3 2024.
  • 87 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.